Clinical Trial Update: Intermediate IND Severe Illness COVID-19 CP [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating convalescent plasma for severe COVID-19 has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Convalescent Plasma (convalescent plasma)

Snippet

Sponsor: Henry Ford Health System | Conditions: Severe Acute Respiratory Syndrome, COVID | Phase 1 | Status: WITHDRAWN